BIXT (Bioxytran) EBIT : $-2.68 Mil (TTM As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Bioxytran EBIT?

Bioxytran's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-0.35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.68 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioxytran's annualized ROC % for the quarter that ended in Sep. 2024 was -130.83%. Bioxytran's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioxytran's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -31.35%.

Bioxytran EBIT Historical Data

The historical data trend for Bioxytran's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran EBIT Chart

Bioxytran Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-1.63

-1.27

-4.21

-2.14

-3.83

Bioxytran Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-1.08	-0.94	-0.79	-0.61	-0.35

Competitive Comparison of Bioxytran's EBIT

For the Biotechnology subindustry, Bioxytran's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxytran's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioxytran's EV-to-EBIT falls into.

Bioxytran EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.68 Mil.

Bioxytran (OTCPK:BIXT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioxytran's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-1.392 * ( 1 - 0% )	/	( (1.02	+	1.108)	/ 2 )
=	-1.392	/	1.064
=	-130.83 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.129	-	0.324	-	( 0.014	-	max(0, 1.229	-	0.014	+	0.014	))
=	1.02

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.159	-	0.26	-	( 0.035	-	max(0, 1.244	-	0.035	+	0.035	))
=	1.108

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioxytran's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.392	/	( ( (0 + max(-0.39, 0))	+	(0 + max(-0.31, 0)) )	/	2 )
=	-1.392	/	( ( 0	+	0 )	/	2 )
=	-1.392	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.324	+	0	+	0.066)
=	-0.39

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.26	+	0	+	0.05)
=	-0.31

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioxytran's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-2.684	/	8.562
	=	-31.35 %

Bioxytran EBIT Related Terms

Thank you for viewing the detailed overview of Bioxytran's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioxytran Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 2nd Avenue, Suite 605, Needham, MA, USA, 02494

Website

https://www.bioxytraninc.com

Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked.

Executives

David Platt	director, 10 percent owner, officer: CEO	12 APPLETON CIRCLE, NEWTON MA 02459
Dale H Conaway	director	189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter	director	BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
Hana Chen-walden	director	7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh	officer: Chief Communication Officer	1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer	other: No longer 10% owner	PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist	10 percent owner, officer: CFO	47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber	director, officer: President	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee	director	78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig	director, officer: Secretary/Treasurer	78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc	10 percent owner	1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai	10 percent owner	20443 TIMBERLINE, BEND OR 97701